BMJ10d
Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
Objectives The Assessment of SpondyloArthritis International Society (ASAS) aimed to develop a set of quality standards (QS) to help improve the quality of healthcare provided to adult patients ...
BMJ4d
Single-cell RNA-seq analysis identifies meniscus progenitors and reveals the progression of meniscus degeneration
Correspondence to Dr Zhiqi Zhang, Department of Joint Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510080, China; zhzhiqi{at}mail.sysu.edu.cn; Dr Weiming Liao; ...
BMJ5d
Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse
1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...
BMJ9d
Wnt16 attenuates osteoarthritis progression through a PCP/JNK-mTORC1-PTHrP cascade
Correspondence to Professor Ling Qin, Prince of Wales Hospital, Hong Kong, China; lingqin{at}cuhk.edu.hk; Professor Kingston King-lun Mak, Joint Center for Musculoskeletal Research, Guangzhou ...
BMJ6d
Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis
Objectives Although T cells have been implicated in the pathogenesis of systemic sclerosis (SSc), a comprehensive study of T-cell-mediated immune responses in the affected skin of patients with ...
BMJ2d
POS1470 POOR LONG-TERM OUTCOMES AND SUBSTANTIAL UNMET NEEDS IN EUROPEAN PATIENTS WITH LUPUS NEPHRITIS
1 University Hospitals of Strasbourg, French National Reference Center for Rare Auto-immune Diseases (RESO), Department of Rheumatology, Strasbourg, France 2 Maple Health Group, LLC, New York, United ...
BMJ3d
AB0502 CELLULAR AND PROTEOMIC CHANGES FOLLOWING ADMINISTRATION OF PERESOLIMAB, IN A PHASE 2A TRIAL IN RHEUMATOID ARTHRITIS
Background: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). Peresolimab demonstrated superiority to placebo in Disease ...
BMJ13d
Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome
Correspondence to Dr Mariana J Kaplan, Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MA ...
BMJ14d
Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications
Objective Autoantibodies against antigens carrying distinct post-translational modifications (PTMs), such as citrulline, homocitrulline or acetyllysine, are hallmarks of rheumatoid arthritis (RA). The ...
BMJ5d
POS0819 ANTI-CD19 CAR T CELL THERAPY IN SYSTEMIC SCLEROSIS – EXPERIENCES FROM TUEBINGEN IN 3 PATIENTS
1 University Hospital Tuebingen, Center for Interdisciplinary Rheumatology, Immunology and Autoimmune Diseases (INDIRA) and Department for Internal Medicine II (Hematology, Oncology, Rheumatology and ...
BMJ14d
Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017
Objectives To report the level and trends of prevalence, incidence and years lived with disability (YLDs) for osteoarthritis (OA) in 195 countries and territories from 1990 to 2017 by age, sex and ...
BMJ10d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...